Q2 FY2026 EarningsQ2 FY26 results significantly beat consensus on both top and bottom lines: revenue was $13.5M vs. $7.7M expected, and GAAP EPS was -$2.44 vs. -$2.71 expected. Growth was primarily driven by the commercial launch of TONMYA, which achieved $11M in net sales (up 197% QoQ). While SG&A and R&D expenses rose significantly to support launch and pipeline activities, the higher-than-expected revenue and improved product mix narrowed losses relative to analyst projections.
Financial report interval: 2026.03.30 - 2026.06.30
Overview: Tonix Pharma(TNXP) the Revenue is 13.54 M (+577.9%), Beat estimate;the EBIT is -42.54 M (-50.32%), Miss estimate;the EPS is -2.44 (+36.79%), Beat estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
RevenueExceed expectations
0.01B577.88%
0.01B286.51%
+0.01B291.37%
EBITMiss expectations
-0.04B50.32%
-0.04B48.73%
-0.00B1.59%
EPSExceed expectations
-2.4436.79%
-2.7129.79%
+0.27007.00%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf